OREANDA-NEWS. Sanofi announced today that it has reached a settlement agreement with Eli Lilly and Company ("Lilly"), which addresses patents on Sanofi's Lantus® SoloSTAR® (insulin glargine). The agreement resolves a U.S. patent infringement lawsuit regarding Lilly's pursuit of regulatory approval for a product that would compete with Lantus SoloSTAR.  Sanofi and Lilly agreed to end that lawsuit and to discontinue similar disputes worldwide. 

Under the agreement, Lilly will pay royalties to Sanofi in exchange for a license to certain Sanofi patents.  In the U.S., Lilly will not sell its insulin glargine product before December 15, 2016. The agreement does not include Lantus (vial), Toujeo® or combination products. The remaining settlement terms are confidential.

Sanofi will continue its commitment to develop and deliver innovations for the more than 387 million people globally living with diabetes.

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).